- Diagnostic Différentiel
- Essayez d'établir votre recherche sur un attribut à la fois, et soyez aussi spécifique que possible! Exemple : "toux chronique".
- Ne pas entrer les résultats multiples tels que "anémie, toux chronique, perte de poids, vomissant" tous en même temps.
- Après sélection de votre attribut, une liste de diagnostics possibles sera générée. Si la liste est trop longue, vous pourrez la réduire en écrivant des attribut additionnels.
- Ne pas écrire les valeurs telles que le "rythme cardiaque 110" ou le "sodium 125", mais plutôt "tachycardie" ou "hyponatrémie".
Drug Information for PIPRACIL (piperacillin for injection) For Intravenous and Intramuscular Use (Wyeth Pharmaceuticals, Inc.): DOSAGE AND ADMINISTRATION
- INDICATIONS AND USAGE
- ADVERSE REACTIONS
- DOSAGE AND ADMINISTRATION
- How Supplied
- Diseases/Conditions Related to PIPRACIL (piperacillin for injection) For Intravenous and Intramuscular Use (Wyeth Pharmaceuticals, Inc.)
- Liens externes liés à PIPRACIL (piperacillin for injection) For Intravenous and Intramuscular Use (Wyeth Pharmaceuticals, Inc.)
PIPRACIL may be administered by the intramuscular route (see NOTE) or intravenously as a three- to five-minute intravenous injection or as a 20- to 30-minute infusion. The usual dosage of PIPRACIL for serious infections is 3 to 4 g given every four to six hours as a 20- to 30-minute infusion. For serious infections, the intravenous route should be used.
PIPRACIL should not be mixed with an aminoglycoside in a syringe or infusion bottle since this can result in inactivation of the aminoglycoside.
The maximum daily dose for adults is usually 24 g/day, although higher doses have been used.
Intramuscular injections (see NOTE) should be limited to 2 g per injection site. This route of administration has been used primarily in the treatment of patients with uncomplicated gonorrhea and urinary tract infections.
DOSAGE RECOMMENDATIONS Type of Infection Usual Total Daily Dose
†One g of probenecid should be given orally one-half hour prior to injection.
Serious infections such as septicemia, nosocomial pneumonia, intra-abdominal infections, aerobic and anaerobic gynecologic infections, and skin and soft tissue infections 12 – 18 g/d I.V. (200 – 300 mg/kg/d) in divided doses every 4 to 6 h Complicated urinary tract infections 8 – 16 g/d I.V. (125 – 200 mg/kg/d) in divided doses every 6 to 8 h Uncomplicated urinary tract infections and most community-acquired pneumonia 6 – 8 g/d I.M. or I.V. (100– 125 mg/kg/d) in divided doses every 6 to 12 h Uncomplicated gonorrhea infections 2 g I.M.† as a one-time dose
The average duration of PIPRACIL treatment is from seven to ten days, except in the treatment of gynecologic infections, which is from three to ten days; the duration should be guided by the patient's clinical and bacteriological progress. For most acute infections, treatment should be continued for at least 48 to 72 hours after the patient becomes asymptomatic. Antibiotic therapy for S. pyogenes infections should be maintained for at least ten days to reduce the risk of rheumatic fever.
When PIPRACIL is given concurrently with aminoglycosides, both drugs should be used in full therapeutic doses.
Dosage in Renal Impairment CreatinineClearancemL/min Urinary TractInfection(uncomplicated) Urinary TractInfection(complicated) SeriousSystemicInfection >40 No dosage adjustment necessary 20-40 No dosage adjustment necessary 9 g/day3 g every 8 h 12 g/day4 g every 8 h <20 6 g/day3 g every 12 h 6 g/day3 g every 12 h 8 g/day4 g every 12 h
For patients on hemodialysis, the maximum daily dose is 6 g/day (2 g every 8 hours). In addition, because hemodialysis removes 30% to 50% of piperacillin in 4 hours, a 1-g additional dose should be administered following each dialysis period.
For patients with renal failure and hepatic insufficiency, measurement of serum levels of piperacillin will provide additional guidance for adjusting dosage.
When possible, PIPRACIL should be administered as a 20- to 30-minute infusion just prior to anesthesia. Administration while the patient is awake will facilitate identification of possible adverse reactions during drug infusion. (See PRECAUTION, Drug Interactions.)
INDICATION 1st Dose 2nd Dose 3rd Dose Intra-abdominal Surgery 2 g I.V. just prior to surgery 2 g during surgery 2 g every 6 h Post-Op for no more than 24 h Vaginal Hysterectomy 2 g I.V. just prior to surgery 2 g 6 h after 1st dose 2 g 12 h after 1st dose Cesarean Section 2 g I.V. after cord is clamped 2 g 4 h after 1st dose 2 g 8 h after 1st dose Abdominal Hysterectomy 2 g I.V. just prior to surgery 2 g on return to recovery room 2 g after 6 h
Pediatric patients. Dosages in pediatric patients under 12 years of age have not been studied in adequate and well-controlled clinical trials (See CLINICAL PHARMACOLOGY).
¶Either Parabens or Benzyl Alcohol.#For Intramuscular Use Only. Lidocaine is contraindicated in patients with a known history of hypersensitivity to local anesthetics of the amide type.
PRODUCT RECONSTITUTION/DOSAGE PREPARATION Conventional Vials: Diluents for Reconstitution Sterile Water for Injection Bacteriostatic¶ Water for Injection Sodium Chloride InjectionBacteriostatic¶ Sodium Chloride Injection Dextrose 5% in Water Dextrose 5% and 0.9% Sodium Chloride Lidocaine# HCl 0.5-1% (without epinephrine)
††When PIPRACIL®is further diluted with Lactated Ringer's Injection, the diluted solution must be administered within 2 hours.
Conventional Vials: Intravenous Solutions Intravenous Admixtures Dextrose 5% in Water 0.9% Sodium Chloride Dextrose 5% and 0.9% Sodium Chloride Lactated Ringer's Injection††Dextran 6% in 0.9% Sodium Chloride Normal Saline [+ KCl 40 mEq]5% Dextrose in Water [+ KCl 40 mEq]5% Dextrose/Normal Saline [+ KCl 40 mEq]Ringer's Injection [+ KCl 40 mEq]Lactated Ringer's Injection [+ KCl 40 mEq]††
Reconstitution Directions for Conventional Vials: Reconstitute each gram of PIPRACIL with at least 5 mL of a suitable diluent (except Lidocaine HCl 0.5%-1% without epinephrine) listed above. Shake well until dissolved. Reconstituted solution may be diluted to the desired volume (eg, 50 or 100 mL) in the above listed intravenous solutions and admixtures.
DIRECTIONS FOR ADMINISTRATIONIntermittent IV InfusionInfuse diluted solution over period of about 30 minutes. During infusion, it is desirable to discontinue the primary intravenous solution.
Intravenous Injection (Bolus) Reconstituted solution should be injected slowly over a 3-to 5-minute period to help avoid vein irritation.
- (Conventional Vials Only)
Reconstitution Directions:Reconstitute each gram of PIPRACIL with 2 mL of a suitable diluent listed above to achieve a concentration of 1 g per 2.5 mL. Shake well until dissolved.
DIRECTIONS FOR ADMINISTRATIONWhen indicated by clinical and bacteriological findings, intramuscularadministration of 6 to 8 g daily of PIPRACIL, in divided doses, may be utilized for initiation of therapy. In addition, intramuscular administration of the drug may be considered for maintenance therapy after clinical and bacteriologic improvement has been obtained with intravenous piperacillin sodium treatment. Intramuscular administration should not exceed 2 g per injection at any one site.
The preferred site is the upper outer quadrant of the buttock (ie, gluteus maximus).
The deltoid area should be used only if well-developed, and then only with caution to avoid radial nerve injury. Intramuscular injections should not be made into the lower or mid-third of the upper arm.
Stability of PIPRACIL Following Reconstitution
PIPRACIL is stable in both glass and plastic containers when reconstituted with recommended diluents and when diluted with the intravenous solutions and intravenous admixtures indicated above.
Pharmacy vials should be used immediately after reconstitution. Discard any unused portion after 24 hours if stored at room temperature (20° to 25°C [68° to 77°F]), or after 48 hours if stored at refrigerated temperature (2° to 8°C [36° to 46°F]). Vials should not be frozen after reconstitution.
- Drug Information Provided by National Library of Medicine (NLM).